Prescription drug sales through the 340B program totaled $38 billion in calendar year 2020, representing 7.2% of overall U.S. sales of $528 billion, Drug Channels blog reports. Drug Channels is run by pharmaceutical manufacturer consultant Adam Fein, a leading critic of the 340B program, particularly of hospitals and contract pharmacies participating in the program.
Drug Channels obtained the data from the U.S. Health Resources and Services Administration (HRSA). HRSA, in its fiscal year 2022 budget request released in late May, reported that in 2019 total sales in the 340B program were approximately $29 billion, representing an estimated 6 percent of the total U.S. drug market.
Prescription drug sales through the 340B program totaled $38 billion in calendar year 2020, representing 7.2% of overall U.S. sales of $528 billion, Drug Channels blog reports. Drug Channels is run by pharmaceutical manufacturer consultant Adam Fein, a leading critic of the 340B program, particularly of hospitals and contract pharmacies participating in the program.
Drug Channels obtained the data from the U.S. Health Resources and Services Administration (HRSA). HRSA, in its fiscal year 2022 budget request released in late May, reported that in 2019 total sales in the 340B program were approximately $29 billion, representing an estimated 6 percent of the total U.S. drug market.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
